My Stock Exchange

My Stock Exchange

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Professional Trial of MYMD-1 as a Therapy for Delaying Aging and also Increasing Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Company”), a professional stage pharmaceutical company committed to prolonging healthy and balanced lifespan, today revealed that the first person has actually been registered in the Business’s Stage 2 scientific test of lead candidate MYMD-1, a dental immune regulatory authority drug, as a treatment for delaying aging and also expanding healthy and balanced life-span.

The key endpoint for the Phase 2 double-blind, placebo-controlled clinical test is to attain a decrease in the distributing levels of (TNF-α), lump death factor receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that cause inflammation as well as assist activate the procedure of aging. The secondary procedures of the test will be the safety and security, tolerability, and pharmacokinetics in this population of clients.

” In a Phase 1 scientific test of MYMD-1, we demonstrated the medicine’s statistically considerable efficacy in decreasing degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has actually authorized TNF-α decrease as the key endpoint for our Stage 2 research, which our company believe settings us well for an effective Phase 2 result,” said Chris Chapman, M.D., Head Of State, Director and Chief Medical Police Officer of MyMD. “The initiation of individual enrollment in this research advancements our goal to reduce the aging process, avoid loss of muscle tissue in aging, restriction frailty, as well as extend healthy life-span.”

MyMD has actually mentioned that there are no FDA-approved medicines for dealing with aging disorders and also expanding healthy and balanced life expectancy human beings, a market expected to be at least $600 billion by 20251 according to a major investment bank. TNF-α blockers are the most proposed medications by revenue, a worldwide market of about $40 billion each year,2 and, according to Nature Aging journal,3 a downturn in aging that would raise life expectancy by one year deserves $38 trillion as well as by ten years deserves $367 trillion.

In addition to aging, MYMD-1’s distinctive action in controling the immune system as well as treating persistent swelling is being established for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetic issues, as well as inflammatory digestive tract condition.

” We intend to start writing protocols for a Stage 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The rising occurrence of rheumatoid arthritis as well as other autoimmune as well as inflammatory diseases are driving need for TNF preventions like MYMD-1, and also our team believe our orally carried out medicine with very reduced toxicity would certainly be disruptive to the $60 billion market for RA if authorized by the FDA for this sign.”

Rheumatoid joint inflammation impacts around 40 million people worldwide.4.

Concerning MYMD-1.

Originally created for autoimmune conditions, MYMD-1’s primary function is to reduce the aging procedure, avoid sarcopenia and frailty, as well as expand healthy life expectancy. Due to the fact that it can go across the blood-brain obstacle and also gain access to the central nerve system (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related problems. Its system of action as well as efficacy in conditions consisting of numerous sclerosis (MS) and thyroiditis have been researched through partnerships with a number of scholastic establishments. MYMD-1 is additionally revealing pledge in pre-clinical research studies as a prospective therapy for article- COVID-19 difficulties and also as an anti-fibrotic as well as anti-proliferation healing.

MYMD-1 has revealed effectiveness in pre-clinical studies in regulating the immune system by carrying out as a selective inhibitor of lump death factor-alpha (TNF-α), a vehicle driver of chronic swelling. Unlike various other treatments, MYMD-1 has actually been received these pre-clinical research studies to selectively block TNF-α when it comes to be overactivated in autoimmune conditions and also cytokine storms, but not obstruct it from doing its typical job of being a first responder to any routine sort of modest infection. MYMD-1’s convenience of oral application is one more differentiator contrasted to currently offered TNF-α blockers, every one of which need delivery by shot or mixture. No approved TNF prevention has ever before been dosed orally. Additionally, the medication is not immunosuppressive and also has actually not been revealed to trigger the severe side effects typical with typical therapies that deal with swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical business devoted to prolonging healthy lifespan, is concentrated on establishing 2 novel restorative systems that deal with the sources of condition rather than just addressing the symptoms. MYMD-1 is a drug system based upon a clinical stage little particle that manages the body immune system to control TNF-α, which drives chronic swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, rise durability, as well as treat autoimmune illness and COVID-19- associated clinical depression. The Company’s 2nd medication system, Supera-CBD, is being developed to treat persistent discomfort, dependency as well as epilepsy. Supera-CBD is an unique synthetic by-product of cannabidiol (CBD) and is being developed to attend to and improve upon the swiftly growing CBD market, which includes both FDA authorized drugs as well as CBD items not currently controlled as medications. To find out more, check out

Francis Snyder

Back to top